Also known as: Versavo
Bevacizumab is a monoclonal antibody anti-angiogenic therapy used in multiple cancers and selected eye disease settings. It is marketed under brand names including Avastin and functions by inhibiting VEGF-A. It has been approved in the U.S. since 2004.
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
A stem cell therapy for geographic atrophy improved vision in a phase Ib trial, and the first gene therapy for optic neuropathies was administered. Next-generation anti-VEGF agents are also extending treatment intervals in retinal vascular disease.
ASCO 2026 data show CBM588 boosts immunotherapy in kidney cancer and a bispecific combo improves lymphoma. Early-day ICI infusion, mezigdomide T cell reinvigoration, and dostarlimab maintenance also advance cancer immunotherapy.
China's 12th national Volume-Based Procurement round places RMB 60 billion across 65 drug varieties, accelerating generics and biosimilars substitution. Separately, Genialis launched BioBridge to help translate Chinese oncology trial results into Western development programs, as Chinese out-licensing hit $137.7 billion in 2025.
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Pfizer reported positive topline PFS results for encorafenib plus cetuximab and FOLFIRI in BRAF V600E-mutant mCRC from BREAKWATER cohort 3. The regimen showed significant PFS improvement and clinically meaningful OS benefit, with no new safety signals.
Phase 3 BREAKWATER found encorafenib plus cetuximab plus FOLFIRI improved PFS and response in first-line BRAF V600E-mutant metastatic colorectal cancer. OS data remain immature.
Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.
The FDA approved Keytruda and Keytruda Qlex with paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian-related cancers. The Phase III KEYNOTE-B96 trial showed improved progression-free and overall survival versus placebo.
Merck received FDA approval in early February 2026 for KEYTRUDA and KEYTRUDA QLEX in PD-L1-positive platinum-resistant ovarian cancer. The decision marks the first approval of a PD-1 inhibitor regimen for this setting.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779538 |
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07776691 |
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07776171 |
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07775287 |
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07774611 |
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07774247 |
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07756840 |
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07743164 |
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07737600 |
A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07728019 |
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM |
NOT_YET_RECRUITING | PHASE2 |
